- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Recombinant human N-acetylgalactosamine-6-sulfatase
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Recombinant human N-acetylgalactosamine-6-sulfatase
| EU orphan designation number: | EU/3/09/657
|
| Active ingredient: | Recombinant human N-acetylgalactosamine-6-sulfatase |
| Indication: | Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome) |
| Sponsor: | BioMarin Europe Ltd.
10 Bloomsbury Way, London WC1A 2SL, United Kingdom |
| EU Centralised marketing authorisation: | A centralised EU marketing authorisation has been obtained under the name Vimizim on 28/04/2014 with the number EU/1/14/914 |
Public summary of scientific opinion
EPAR
European Commission procedures |


